47 results
8-K
EX-99.1
PRME
Prime Medicine Inc
10 May 24
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
8:05am
for neuromuscular programs in 2024.
First Quarter 2024 Financial Results
Research and Development (R&D) Expenses: R&D expenses were $37.8 million … ; the initiation, timing, progress, and results of its research and development programs, preclinical studies and future clinical trials, and the release
PRE 14A
PRME
Prime Medicine Inc
19 Apr 24
Preliminary proxy
4:07pm
., a biotechnology company and a director and member of the research and development committee of Intercept Pharmaceuticals, Inc. He received his M.D. from … , participation in corporate and research and development strategy sessions, recruiting and interviewing activities, finding and establishing
8-K
EX-99.1
c6koy
1 Mar 24
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
8:01am
8-K
88i9pdzmpv m9ti
16 Feb 24
Entry into a Material Definitive Agreement
6:23am
424B5
hv39thaalnjxuqpo
16 Feb 24
Prospectus supplement for primary offering
6:17am
FWP
tbezls0h0eo 1e
14 Feb 24
Free writing prospectus
9:57pm
424B5
sxgay5nkpue0du
14 Feb 24
Prospectus supplement for primary offering
5:27pm
8-K
EX-99.1
xz8e lbr0qie2
8 Jan 24
Regulation FD Disclosure
8:01am
S-3
fgagj o2ck
3 Nov 23
Shelf registration
5:23pm
8-K
EX-99.1
95kxl8c7d 5hbu3y97
3 Nov 23
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
4:06pm
8-K
EX-99.2
npmq9q ygry
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
8-K
EX-99.1
56vbhcoh7ot1qe
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
8-K
EX-99.1
ixalxft7r em3ppt2
17 May 23
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
7:09am